RxDoctor Payments Data

Craig Steiner, MD

Family Medicine · Idaho Falls, IDNPI 1710477500

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 444 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 60 manufacturers reported payments, led by AbbVie at 31.8% of the total. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,408in general payments, 2019–2025

Across 444 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$396
  • Amgen$342
  • Axsome Therapeutics, Inc.$297
  • Boehringer Ingelheim$296
  • Otsuka America Pharmaceutical, Inc.$295
  • plus $3K from 54 others

What the payments were for

  • Food & beverage$7,385100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie131$2,354
Novo Nordisk34$396
Amgen(2 entities)19$342
Axsome Therapeutics, Inc.20$297
Boehringer Ingelheim15$296
Otsuka America Pharmaceutical, Inc.20$295
Lilly USA, LLC26$268
Astellas Pharma US Inc8$224
Vanda Pharmaceuticals Inc.9$211
Novartis11$182
Bayer11$171
Antares Pharma, Inc.9$171
Lundbeck LLC6$136
GSK9$134
AstraZeneca7$117
Merck7$116
Boston Scientific6$107
CSL Behring4$104
Teva Pharmaceuticals USA, Inc.6$94
Dexcom, Inc.4$87
Phathom Pharmaceuticals, Inc.8$80
Shield Therapeutics Inc4$75
Corium, LLC8$75
Averitas Pharma Inc.2$65
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$64
Pfizer4$59
Corcept Therapeutics3$57
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$56
Supernus Pharmaceuticals, Inc.3$49
Johnson & Johnson3$48
Genentech USA, Inc.3$44
Ironshore Pharmaceuticals Inc.2$43
Biocryst US Sales Co., LLC2$43
Nestle Healthcare Nutrition Inc.2$42
Alnylam Pharmaceuticals Inc.2$37
Sanofi Pasteur Inc.2$37
Neurocrine Biosciences, Inc.2$35
Neurelis, Inc.2$34
Ionis Pharmaceuticals, Inc.1$26
Takeda Pharmaceuticals U.S.A., Inc.2$26
BD1$22
Aimmune Therapeutics, Inc.1$19
Sumitomo Pharma America, Inc.1$19
Ultragenyx Pharmaceutical Inc.1$18
Seqirus USA Inc1$18
Acadia Pharmaceuticals Inc1$18
Mylan Specialty L.p.1$17
Edwards Lifesciences1$16
Regeneron Healthcare Solutions, Inc.1$15
Amarin Pharma, Inc.1$15
Pharming Healthcare, Inc.1$15
Xeris Pharmaceuticals, Inc.1$15
Exact Sciences1$14
Daiichi Sankyo Inc.1$14
Collegium Pharmaceutical, Inc.1$14
Tactile Systems Technology Inc1$14
E.r. Squibb & Sons, L.L.C.1$13
Biohaven Pharmaceutical Holding Company Ltd.1$13
Sanofi-aventis U.S. LLC1$12
Jazz Pharmaceuticals Inc.1$12

How this compares

$7,408 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$101,509
Medicare patients
318
Services billed
1,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$48,057
MounjaroTirzepatide36$36,527
OzempicSemaglutide19$33,510
FarxigaDapagliflozin Propanediol29$27,143
EliquisApixaban33$21,995
TrintellixVortioxetine Hydrobromide24$11,557
Lamotrigine ErLamotrigine13$7,600
Repatha SureclickEvolocumab12$6,455
Memantine Hcl ErMemantine Hcl24$6,435
VascepaIcosapent Ethyl11$3,928
Celecoxib47$3,666
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,419
Pregabalin18$2,776
Ondansetron Hcl13$2,567
Venlafaxine Hcl ErVenlafaxine Hcl25$2,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$296$48,05746 claims
Lilly USA, LLCMounjaro$268$36,52736 claims
Novo NordiskOzempic$396$33,51019 claims
AstraZenecaFarxiga$117$27,14329 claims
PfizerEliquis$59$21,99533 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$11,55724 claims
GSKShingrix$134$3,41916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.

Other family medicine in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →